Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, United States of America.
J Neural Eng. 2017 Oct;14(5):051002. doi: 10.1088/1741-2552/aa7a27. Epub 2017 Aug 22.
Inherited retinal degenerations are a clinically and genetically heterogeneous group of conditions that have historically shared an untreatable course. In recent years, however, a wide range of therapeutic strategies have demonstrated efficacy in preclinical studies and entered clinical trials with a common goal of improving visual function for patients affected with these conditions. Gene therapy offers a particularly elegant and precise opportunity to target the causative genetic mutations underlying these monogenic diseases. The present review will provide an overview of gene therapy with particular emphasis on key clinical results to date and challenges for the future.
遗传性视网膜退行性疾病是一组临床和遗传异质性的疾病,其历史上一直具有不可治疗的病程。然而,近年来,广泛的治疗策略已在临床前研究中显示出疗效,并进入临床试验,其共同目标是改善受这些疾病影响的患者的视觉功能。基因治疗为针对这些单基因疾病的潜在致病基因突变提供了一个特别优雅和精确的机会。本综述将提供基因治疗的概述,特别强调迄今为止的关键临床结果和未来的挑战。